Document Detail

Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions.
MedLine Citation:
PMID:  17537784     Owner:  NLM     Status:  MEDLINE    
AIMS: To determine the characteristics of "non-responders" to intravitreal bevacizumab treatment in choroidal neovascularisation (CNV).
METHODS: Forty-three patients with visual loss due to neovascular age-related macular disease (ARMD) (44 eyes) underwent intravitreal injections of 1.25 mg (0.05 ml) bevacizumab and were followed up every 4 weeks for 2, 3 or 6 months. Re-injection was performed when persistent leakage of the CNV was determined by fluorescein angiography and retinal oedema was assessed by optical coherence tomography (OCT). Non-responders were defined as those patients having reduced or stable visual acuity at the last follow-up.
RESULTS: 45% of the patients were non-responders. In this group the initial CNV size was significantly larger than in the responders. Initial reading ability was significantly lower in non-responders, but the initial foveal oedema was similar in both groups. Gains in mean visual acuity and reading ability were independent of lesion type. The proportion of non-responders to responders in the different lesion type groups was equally distributed. Only patients with the classic type of CNV seemed to respond better.
CONCLUSIONS: In this study initial reasons for non-responders to intravitreal bevacizumab treatment in CNV are given. The efficiency of bevacizumab depends on initial lesion size and initial reading ability, but is independent of the amount of intraretinal and subretinal fluid. There was no general ineffectiveness of bevacizumab with any particular lesion type.
Anja Lux; Helene Llacer; Florian M A Heussen; Antonia M Joussen
Related Documents :
7522004 - Evaluation of argon green vs krypton red laser for photocoagulation of subfoveal choroi...
11584844 - Long-term follow-up of lid surgery for trichiasis in the gambia: surgical success and p...
17539784 - Factors influencing poor visual outcome in patients treated with photodynamic therapy f...
18303234 - Meta-analysis of chromovitrectomy with indocyanine green in macular hole surgery.
21110094 - Injections of botulinum toxin a into the detrusor to treat neurogenic detrusor overacti...
22931744 - Cervical rib, a rare cause of recurrent stroke in the young: case report.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-05-30
Journal Detail:
Title:  The British journal of ophthalmology     Volume:  91     ISSN:  0007-1161     ISO Abbreviation:  Br J Ophthalmol     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-09-26     Completed Date:  2007-10-26     Revised Date:  2013-06-06    
Medline Journal Info:
Nlm Unique ID:  0421041     Medline TA:  Br J Ophthalmol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1318-22     Citation Subset:  IM    
Department of Ophthalmology, University of Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Choroidal Neovascularization / drug therapy*,  pathology,  physiopathology
Edema / pathology
Fluorescein Angiography / methods
Fovea Centralis / pathology
Prospective Studies
Retinal Diseases / complications,  pathology
Treatment Failure
Visual Acuity / physiology
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab
Comment In:
Br J Ophthalmol. 2007 Oct;91(10):1259-60   [PMID:  17895411 ]
Br J Ophthalmol. 2008 Jun;92(6):864-5; author reply 865-6   [PMID:  18523095 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The accuracy of accredited glaucoma optometrists in the diagnosis and treatment recommendation for g...
Next Document:  Intravenous administration of clonidine reduces intraocular pressure and alters ocular blood flow.